Exhibit 10.1
INTELLECTUAL PROPERTY CROSS-LICENSE AGREEMENT
This INTELLECTUAL PROPERTY CROSS-LICENSE AGREEMENT (this “Agreement”), dated as of May 17, 2021 (the “Effective Date”), is made between SPINALCYTE LLC, a Texas limited liability company (“SpinalCyte”) and FIBROBIOLOGICS LLC, a Texas limited liability company (“FibroBiologics”). FibroBiologics and SpinalCyte are each referred to individually as a “Party” and collectively as the “Parties.”.
WHEREAS, SpinalCyte owns 100% of the rights, title and interest in the SpinalCyte Licensed IP (as defined below);
WHEREAS, SpinalCyte desires to grant and FibroBiologics desires to accept an exclusive license to FibroBiologics to practice the SpinalCyte Licensed IP in a limited field of use;
WHEREAS, FibroBiologics owns 100% of the rights, title and interest in the FibroBiologics Licensed IP (as defined below); and
WHEREAS, FibroBiologics desires to grant and SpinalCyte desires to accept an exclusive license to SpinalCyte to practice the FibroBiologics Licensed IP in a limited field of use.
NOW THEREFORE, in consideration of the ongoing financial and other support provided by FibroBiologics to SpinalCyte and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, FibroBiologics and SpinalCyte hereby agree as follows:
ARTICLE 1 DEFINITIONS
“Affiliate” means, with respect to a Party, any Person that controls, is controlled by, or is under common control with such Party, where “control” means the possession, directly or indirectly, through one or more intermediaries, of the power to direct or cause the direction of the management or policies of a Person, whether through ownership of voting securities, controlling interests or similar arrangement.
“Exploit” means to make, have made, import, use, sell or offer for sale, including to research, develop, commercialize, register, manufacture, have manufactured, hold or keep (whether for disposal or otherwise), have used, export, transport, distribute, promote, market, sell, have sold, dispose of, copy, distribute, create derivative works of, publicly perform or publicly display.
“FibroBiologics Licensed Field of Use” means, collectively, the diagnosis, treatment, prevention and palliation of (a) spinal diseases, disorders or conditions, (b) cancer, (c) orthopedics diseases, disorders or conditions and (4) multiple sclerosis.
“FibroBiologics Licensed IP” means the intellectual property set forth and described in Schedule 1 to this Agreement.
“FibroBioLogics Licensed Product(s)” means any product, process or service that incorporates, utilizes or is made with the use of the SpinalCyte Licensed IP.
“Licensed IP” means the FibroBiologics Licensed IP and the SpinalCyte Licensed IP, collectively.
| -1- |
“Licensee” means the Party receiving rights under a license grant pursuant to this Agreement. Depending on the context, Licensee may mean either or both of SpinalCyte and FibroBiologics.
“Patent Owner” means the owner of a patent within the Licensed IP. Depending on the context, Patent Owner may mean either or both of SpinalCyte and FibroBiologics.
“Person” means an individual, corporation, partnership, joint venture, limited liability company, governmental authority, unincorporated organization, trust, association or other entity.
“Prosecute and Maintain” means with regard to a patent, the preparing, filing, prosecuting and maintenance of such patent, as well as handling re-examinations and reissues with respect to such patent, together with the conduct of interferences, the defense of oppositions and other similar proceedings with respect to the particular patent. For clarification, Prosecute and Maintain does not include any other enforcement actions taken with respect to a patent.
“SpinalCyte Licensed Field of Use” means any and all fields of use other than the FibroBiologics Licensed Field of Use, and specifically includes (without limitation) Alzheimer’s and other dementia related diseases, diabetes, cachexia, tissue regeneration, stroke, addiction, miscarriages, inflammatory bowel disease, transplant rejections, cerebral palsy, sclerosing cholangitis, Parkinson’s disease, erectile dysfunction, allergy, asthma, concussive neurological damage, encephalopathy, blindness, aneurysms, ovarian failure, dysbiosis, cerebral hemorrhage, acute respiratory distress syndrome, COVID, pathological immune response, dental/periodontal, and alopecia.
“SpinalCyte Licensed IP” means the intellectual property set forth and described in Schedule 2 to this Agreement.
“SpinalCyte Licensed Product(s)” means any product, process or service that incorporates, utilizes or is made with the use of the FibroBiologics Licensed IP.
ARTICLE 2 LICENSE GRANTS
SpinalCyte License Grant to Fibrobiologics. Subject to the terms and conditions of this Agreement, SpinalCyte hereby grants to FibroBiologics, and FibroBiologics hereby accepts, a worldwide, perpetual, irrevocable, fully paid up, royalty-free, exclusive, transferable, sub-licensable license to the SpinalCyte Licensed IP, to Exploit Licensed Product(s) in the FibroBiologics Licensed Field of Use.
FibroBiologics License Grant to SpinalCyte. Subject to the terms and conditions of this Agreement, FibroBiologics hereby grants to SpinalCyte, and SpinalCyte hereby accepts, a worldwide, perpetual, irrevocable, fully paid up, royalty-free, exclusive, transferable, sub licensable license to the FibroBiologics Licensed IP, to Exploit Licensed Product(s) in the SpinalCyte Licensed Field of Use.
Exclusivity. For the avoidance of doubt, the licenses in Section 2.1 and Section 2.2 are exclusive within their respective fields of use even as to the granting licensor.
No Implied Licenses. Except as otherwise specifically set forth herein, only the licenses granted pursuant to the express terms of this Agreement shall be of any legal force and effect. No license or other intellectual property rights shall be created by implication in any patents, technology and/or proprietary information owned by a Party, even if such patents, technology, or proprietary information is necessary to exploit the Licensed IP.
| -2- |
ARTICLE 3
PATENT PROSECUTION AND MAINTENANCE; PATENT ENFORCEMENT
Patent Prosecution and Maintenance. Each Party, as Patent Owner, shall diligently and in good faith Prosecute and Maintain any and all patent applications and patents owned by such Party that are included in the Licensed IP, at its own cost. If a Patent Owner decides not to: (i) prosecute certain patent applications within the Licensed IP to issuance or (ii) maintain any United States or foreign issued patent within the Licensed IP, the Patent Owner shall timely notify the Licensee of such patent right in writing thereof and upon written request by the Licensee, the Parties shall cooperate to transfer the ownership of such patent right to the Licensee, provided, that the Patent Owner shall retain an a worldwide, irrevocable, fully paid up, royalty-free, exclusive, transferable, sublicensable license to and under the transferred patent right to Exploit Licensed Products in its field of use. The preceding sentence shall not apply to any patent applications within the Licensed IP that will be abandoned for the pursuit of a utility application in the case of a provisional application, a divisional or continuation application in the case of any utility application, any national stage applications in the case of a patent cooperation treaty application, or countries not validated in the case of a European or other regional patent application.
Infringement Procedures. During the term of this Agreement, each Party shall promptly inform the other of any suspected infringement, misuse, misappropriation, theft or breach of confidence of other proprietary rights in the Licensed IP by a third party (collectively “Third Party Activities”), and with respect to such activities as are suspected. For Third Party Activities involving a Licensee’s exclusive field of use, the Licensee shall have the first right, but not the obligation, to institute an action or proceeding against Third Party Activities and defend any declaratory judgment action relating thereto. The Patent Owner shall have the right, but not the obligation, to join any such suit, legal action or proceeding that is initiated by the Licensee, at the Licensee’s cost. The Patent Owner shall, where necessary, furnish a power of attorney solely for such purpose, or be named as a necessary party to, such action, at the Licensee’s cost. If the Licensee fails to bring such an action or proceeding within the earlier of (a) a period of three (3) months after receiving notice or otherwise having knowledge of such Third Party Activities, or (b) thirty (30) days before the time limit, if any, set forth in the applicable law or regulations for the filing of or response to such suit action or proceeding, whichever comes first, then the Patent Owner shall have the right, but not the obligation, to prosecute the same solely with respect to the activities at its own expense. The Party not instituting the action or the proceeding (the “Non-Instituting Party”) will reasonably cooperate with the Party instituting the action or the proceeding (the “Instituting Party”) in such action. In addition, notwithstanding anything to the contrary contained herein, if the Non-Instituting Party cooperates in such action, such cooperation shall be at the Instituting Party’s sole expense. Should either the Patent Owner or the Licensee commence action under the provisions of this Section 3.2 and thereafter elect to abandon the same, it shall give timely notice to the other Party who may, if it so desires, continue prosecution of such action or proceeding. All recoveries, whether by judgment, award, decree or settlement, from infringement or misuse of Licensed IP under this Section 3.2 shall be apportioned as follows: (a) the Instituting Party shall first recover an amount equal the costs and expenses incurred by such Party directly related to the prosecution of such action or proceeding, (b) the Non-Instituting Party shall then recover costs and expenses incurred by such Party, if any, directly related to its cooperation in the prosecution of such action or proceeding and (c) the remainder shall be shared by the Parties, with the Party bringing the action allocated eighty percent (80%) and the Party cooperating in such action allocated twenty percent (20%) of such amounts, such amount not to exceed $1,000,000.
Consent to Settle. Neither Party shall settle any action covered by Section 3.2 without first obtaining the consent of the other Party, which consent will not be unreasonably withheld.
Defense of Infringement Claims. If any third party asserts a claim, demand, action, suit or proceeding against a Licensee (or any of its sublicensees), alleging that any Licensed Product or that the use or practice of the Licensed IP infringes, misappropriates or violates the intellectual property rights of any Person (any such claim, demand, action, suit or proceeding being referred to as and “Infringement Claim”), the Licensee shall promptly notify the Patent Owner in writing specifying the facts, to the extent known, in reasonable detail. In the case of any such Infringement Claim, the Licensee shall assume control of the defense and shall have the exclusive right to settle any Infringement Claim against the Licensee without the consent of the Patent Owner; provided, however, if such settlement requires any payment from the Patent Owner or decreases the Patent Owner’s rights under this Agreement, the Licensee shall be required to obtain the Patent Owner’s consent, which consent will not be unreasonably withheld.
| -3- |
ARTICLE 4 TERM
Term. This Agreement shall commence upon the Effective Date and expire, on a country-by-country basis, on the date of expiration of the last valid claim of the patent rights in the Licensed IP.
ARTICLE 5 INDEMNIFICATION
FibroBiologics Indemnity. FibroBiologics shall indemnify, defend, and hold harmless SpinalCyte, its Affiliates, and their respective shareholders, members, managers, directors, officers, employees, personnel and agents (collectively, the “SpinalCyte Indemnified Parties” and each an “SpinalCyte Indemnified Party”) from and against all claims, actions, causes of action or demands, (including liabilities, costs, expenses, reasonable attorneys’ fees, damages and losses resulting from the foregoing) (collectively, “Claims”) brought by or on behalf of a third party arising out of or in connection with: (a) any violation of applicable law by FibroBiologics, its Affiliates or its sublicensees; (b) any claim that a FibroBiologics Licensed Product or that the use of the SpinalCyte Licensed IP by Fibrobiologics, its Affiliates or its sublicensees infringes, misappropriates or otherwise violates any intellectual property rights of any third party; and (c) FibroBiologics’, its Affiliates or its sublicensees gross negligence, willful misconduct or fraudulent conduct. FibroBiologics shall not be responsible to, nor shall it indemnify any SpinalCyte Indemnified Party for any Claims to the extent arising from any negligent act or omission or willful misconduct of an SpinalCyte Indemnified Party and its shareholders, members, managers, directors, officers, employees, personnel and agents, and those for whom in law SpinalCyte is responsible for. This Section 5.1 shall survive any termination or expiration of this Agreement.
SpinalCyte Indemnity. SpinalCyte shall indemnify, defend, and hold harmless FibroBiologics, its Affiliates, and their respective shareholders, members, managers, directors, officers, employees, personnel and agents (collectively, the “FibroBiologics Indemnified Parties” and each a “FibroBiologics Indemnified Party”) from and against any Claims brought by or on behalf of a third party arising out of or in connection with: (a) any violation of applicable law by SpinalCyte, its Affiliates or its sublicensees; (b) any claim that a SpinalCyte Licensed Product or that the use of the FibroBiologics Licensed IP by SpinalCyte, its Affiliates or its sublicensees infringes, misappropriates or otherwise violates the intellectual property rights of any third party; (c) SpinalCyte’s, its Affiliates’ or its sublicensees gross negligence, willful misconduct or fraudulent conduct. SpinalCyte shall not be responsible to, nor shall it indemnify a FibroBiologics Indemnified Party for any Claims to the extent arising from any negligent act or omission or willful misconduct of FibroBiologics, its Affiliates, and those for whom in law FibroBiologics is responsible for. This Section 5.2 shall survive any termination or expiration of this Agreement.
Procedure. The indemnified Party shall promptly notify the indemnifying Party in writing of any Claim for which it believes it is entitled to indemnification hereunder. Failure or delay in providing such notice shall not relieve the indemnifying Party of its indemnification obligations, except to the extent the indemnifying Party demonstrates that the defense or settlement of the Claim has been prejudiced thereby. Subject to prov1s1ons below in this Section 5.3, the indemnifying Party shall have the right to control the defense and settlement of any Claim, or may at any time tender control of the defense or settlement of such Claim to the indemnified Party. The indemnified Party shall have the right to approve of counsel retained by the indemnifying Party for such Claim (such approval not to be unreasonably withheld, conditioned or delayed), and may, at its own cost, elect to participate in the defense or settlement of any Claim with counsel of its choice. No compromise or settlement other than solely for an amount of money may be committed to by the indemnifying Party without the indemnified Party’s prior written approval (which shall not be unreasonably withheld, conditioned or delayed).
| -4- |
ARTICLE 6 LIMITATION OF LIABILITY
WAIVER OF CONSEQUENTIAL DAMAGES. EXCEPT WITH RESPECT TO EACH PARTY’S INDEMNIFICATION OBLIGATIONS PURSUANT TO ARTICLE 5, FRAUD OR INTENTIONAL MISCONDUCT, IN NO EVENT SHALL EITHER PARTY, ITS DIRECT OR INDIRECT SUBSIDIARIES, AFFILIATES, DIRECTORS, OFFICERS, AGENTS, EMPLOYEES OR REPRESENTATIVES BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, PUNITIVE, EXEMPLARY OR CONSEQUENTIAL DAMAGES OF ANY KIND, NOR FOR ANY LOST PROFITS OR REVENUES, IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT.
LIMITATION OF LIABILITY. EXCEPT FOR EACH PARTY’S INDEMNIFICATION OBLIGATIONS PURSUANT TO ARTICLE 5, OR GROSS NEGLIGENCE OR FRAUD OR INTENTIONAL MISCONDUCT, THE MAXIMUM AGGREGATE LIABILITY OF EITHER PARTY TO THE OTHER, FOR ANY REASON AND UPON ANY CAUSE OF ACTION ARISING OUT OF OR RELATING TO THIS AGREEMENT SHALL BE LIMITED TO AN AMOUNT NOT TO EXCEED $1,000,000, EVEN IF A PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES OR SUCH DAMAGES ARE REASONABLY FORESEEABLE. THE FOREGOING LIMITATIONS SHALL APPLY REGARDLESS OF THE CAUSE OR FORM OF ACTION, WHETHER BASED IN CONTRACT, TORT, NEGLIGENCE, STRICT LIABILITY, WARRANTY OR OTHERWISE AND SHALL: NEVER BE DEEMED TO FAIL IN THEIR ESSENTIAL PURPOSE.
ARTICLE 7 CONFIDENTIALITY
Definition. For purposes of this Agreement, “Confidential Information” of a Party means any non-public information or materials belonging to, concerning or in the possession or control of such Party or its Affiliates (the “Disclosing Party”) that is furnished, disclosed or otherwise made available (directly or indirectly) to the other Party (or Persons acting on such other Party’s behalf) (the “Receiving Party”) in connection with this Agreement and which is either marked or identified as confidential or proprietary or is of a type that a reasonable person would recognize it to be confidential or proprietary.
| -5- |
Confidentiality Obligations. During the term and for a period of two (2) years thereafter, or in the event an item is a trade secret, so long as the item remains a trade secret, the Receiving Party shall: (a) hold the Confidential Information in strict confidence and avoid the disclosure thereof to any third party by using the same degree of care as it uses to avoid the unauthorized use or disclosure of its own Confidential Information of a similar nature, but not less than reasonable care; and (b) not use the Confidential Information for any purpose except as contemplated under this Agreement. Should a Party become possessed of a trade secret of a Disclosing Party under the terms of this Agreement, the Receiving Party shall not, during the term and thereafter, use or disclose such trade secret. The Receiving Party shall restrict the possession and use of Confidential Information to its personnel who have a need to know and are bound by confidentiality obligations no less stringent than those contained herein. The Receiving Party may disclose Confidential Information as required by applicable law, provided the Receiving Party discloses only such information as is required by applicable law and, if permitted by applicable law, uses reasonable efforts to notify the Disclosing Party of such disclosure in sufficient time to allow the Disclosing Party to seek a protective order or similar confidential treatment at Disclosing Party’s expense. The Receiving Party shall promptly notify the Disclosing Party of any facts known to the Receiving Party regarding any unauthorized disclosure or use of Confidential Information. Each Party acknowledges that its breach of the obligations set forth in this Section 7.2 may cause irreparable harm for which the other Party shall be entitled to seek injunctive or other equitable relief. All Confidential Information shall remain the exclusive property of the Disclosing Party.
Limitations. Confidential Information shall not include any information that: (a) was demonstrably known by the Receiving Party before disclosure by the Disclosing Party, (b) becomes generally publicly known or otherwise known to the Receiving Party after such disclosure, other than by breach of a confidentiality obligation; or (c) is independently developed by the Receiving Party by persons without access to such information.
Return or Destruction of Confidential Information. Upon termination of this Agreement for any reason or upon the other Party’s written request, each Party shall promptly:
(a) return or destroy, at the other Party’s direction, all material embodying the Confidential Information of the other Party in such Party’s possession, custody or control; and (b) if requested by the other Party, deliver an affidavit certifying that such Party has complied with the obligations set forth herein.
Residual Rights. Each Party acknowledges and agrees that the other Party, its Affiliates and their respective employees and agents shall be free to use and employ their general skills, ideas, concepts, know-how and expertise, and to use, disclose, and employ any generalized ideas, concepts, know-how, methods, techniques or skills gained or learned during the course of any activities performed hereunder, subject to its obligations respecting the other Party’s Confidential Information pursuant to this Article 7.
| -6- |
ARTICLE 8 REPRESENTATIONS AND WARRANTIES.
Mutual Representations and Warranties. Each Party represents and warrants to the other that they each have: (a) all requisite legal and corporate power to execute and deliver this Agreement; (b) taken all corporate action necessary for the authorization, execution and delivery of this Agreement; (c) no agreement or understanding with any third party that interferes with or will interfere with the performance of their respective obligations under this Agreement; (d) obtained and shall maintain all rights, approvals and consents necessary to perform their respective obligations under this Agreement; (e) taken all action required or necessary to make such agreements legal, valid and binding obligations upon them; and (f) it has the right to grant the licenses to the other which are granted in this Agreement.
Disclaimer. NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY OF ANY KIND, WHETHER EXPRESS OR IMPLIED, EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES EXPRESSLY SET FORTH IN THIS SECTION 8.1, AND EACH PARTY EXPRESSLY DISCLAIMS ANY IMPLIED OR STATUTORY WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, QUALITY, TITLE OR ANY REPRESENTATION OR WARRANTY ARISING FROM COURSE OF PERFORMANCE, COURSE OF DEALING OR USAGE OF TRADE.
ARTICLE 9 ADDITIONAL PROVISIONS
Further Assurances. Each Party covenants and agrees to execute and deliver or cause to be executed and delivered to the other Parties such instruments or further assurances as may, in the reasonable opinion of such other Party, be necessary or desirable to give effect to the provisions of this Agreement.
Notices. All notices required or permitted under this Agreement shall be in writing and delivered via overnight mail or overnight courier service, signature proof of receipt required. Notices shall be directed to the addresses set forth below and shall be deemed effective upon receipt. Either Party may change its address for notices from time to time by providing written notice to the other Party.
If to SpinalCyte:
President of SpinalCyte PO Box 891146
Houston, Texas 77289
| -7- |
If to FibroBiologics:
President of SpinalCyte PO Box 891146
Houston, Texas 77289
Assignment. The Agreement shall be binding on the Parties and their successors and permitted assigns. Neither Party shall assign, transfer or delegate any of its rights, duties or obligations under this Agreement, or any part thereof, whether by operation of law or otherwise, without the prior written consent of the other Party, provided that either Party shall be entitled to assign or transfer this Agreement in connection with the sale or acquisition of its business to which this Agreement relates, whether by merger, sale of stock, sale of assets or otherwise. Any assignment in violation of this paragraph shall be void ab initio.
Publicity; Press Releases. Neither Party shall, without the prior written consent of the other Party which shall not be unreasonably withheld, issue any press releases or make any public statements concerning the existence of or activities under this Agreement or disclose the terms of this Agreement to any third party other than its legal, financial and other advisors under a duty of confidentiality. The Parties will mutually agree upon the content and timing of any press release announcing the execution of this Agreement or otherwise relating to the terms of this Agreement.
Modifications; Waiver. This Agreement may be modified only pursuant to a writing executed by authorized representatives of both Parties. The Parties expressly disclaim the right to claim the enforceability of any oral modifications to this Agreement or any amendments based on course of dealing, waiver, reliance, estoppel or other similar legal theory. No delay or omission by either Party to exercise any right occurring upon any non-compliance or default of the other Party with respect to any of the terms of this Agreement shall impair any such right or be construed to be a waiver thereof.
No Third Party Beneficiaries. This Agreement is for the sole benefit of the Parties and their successors and permitted assigns and nothing herein, express or implied, shall give or be construed to give any Person other than the Parties any legal or equitable rights hereunder.
Severability. In the event any provision of this Agreement is determined by a court of competent jurisdiction to be invalid or unenforceable under applicable law, such provision shall be amended and interpreted to accomplish the objectives of such provision to the greatest extent possible under applicable law, and the remaining provisions of this Agreement shall continue in full force and effect.
Arbitration. The Parties agree that any and all disputes, claims or controversies arising out of or related to this Agreement, including any claims under any statute or regulation (“Disputes”), shall be submitted first to non-binding mediation. If the Disputes are not resolved through mediation, then, upon the election of either Party, the Disputes shall be submitted for binding arbitration. Unless the Parties agree otherwise, any mediation and arbitration shall take place in the State of Texas, Harris County, and shall be administered by, and pursuant to the rules of, the American Arbitration Association (“AAA”).
| -8- |
Governing Law; Jurisdiction. This Agreement shall be governed by and construed in accordance with the laws of New York, without reference to the principles of conflicts of law that would apply the substantive laws of another jurisdiction. In the event a court or other tribunal of competent jurisdiction rules that Section 9.9 or any provision therein is invalid or otherwise unenforceable, each Party hereby submits to the exclusive jurisdiction of the state and federal courts located in [Harris County, Texas] over any Disputes arising out of or relating to this Agreement and waives the right to object to such venue or make a claim of forum non conveniens. Notwithstanding the foregoing, nothing herein shall prevent either Party from commencing an action for the purpose of seeking immediate injunctive relief in the appropriate jurisdiction.
Survival. Any provision of this Agreement that contemplates performance or observance subsequent to any expiration or termination of this Agreement, or which is otherwise necessary to interpret the respective rights and obligations of the Parties hereunder, shall survive any expiration or termination of this Agreement and continue in full force and effect, including without limitation Article 1 (General), Article 5 (Indemnification), Article 6 (Limitation of Liability), Article 7 (Confidentiality), and Article 9 (Additional Provisions).
Headings; Construction. The headings of the various sections in this Agreement are for convenience of reference only and shall not affect the construction or interpretation of this Agreement or this Agreement. The Parties acknowledge and agree that any principle of construction or rule of law that provides that an agreement shall be construed against the drafter of the agreement in the event of any inconsistency or ambiguity in such agreement shall not apply to the terms and conditions of this Agreement.
Entire Agreement. This Agreement, together with the Schedules attached hereto, sets forth the entire and exclusive agreement between the Parties as to the subject matter hereof and supersedes all prior and contemporaneous understandings, negotiations and agreements, written or oral, between the Parties.
Counterparts. This Agreement may be executed in several counterparts, including by e-mail and with electronic signatures, each of which will be deemed an original, and all of which taken together shall constitute one single agreement between the Parties with the same effect as if all the signatures were upon the same instrument. An electronic signature shall be as legally effective as an original signature.
[SIGNATURE PAGE FOLLOWS]
| -9- |
IN WITNESS WHEREOF, the Parties have duly executed and delivered this Agreement as of the date first above written.
| FIBROBIOLOGICS LLC | ||
| By: | /s/ Pete O’Heeron | |
| Name: | Pete O’Heeron | |
| Title: | Manager | |
| SPINALCYTE LLC | ||
| By: | /s/ Pete O’Heeron | |
| Name: | Pete O’Heeron | |
| Title: | CEO | |
| -10- |
Schedule 1
FibroBiologics Licensed IP
| Docket Number | Country | Appl. No. | Date Filed | Reg. No. | Title | |||||
| AMTK.P0002AU.D1 | Australia | 2011253785 | 12/2/2011 | 2011253785 | METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR | |||||
| AMTK.P0002AU.D2 | Australia | 2013257540 | 11/19/2013 | 2013257540 | METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR | |||||
| AMTK.P0002AU.D3 | Australia | 2015202319 | 5/6/2015 | 2015202319 | METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR | |||||
| AMTK.P0002AU.D4 | Australia | 2017206234 | 7/20/2017 | 2017206234 | METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR | |||||
| AMTK.P0002AU.D5 | Australia | 2018220112 | 8/23/2018 | 2018220112 | METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR | |||||
| AMTK.P0002CN.D1 | China | 201110261353.3 | 8/9/2011 | ZL 201110261353.3 | METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR |
| -11- |
| Docket Number | Country | Appl. No. | Date Filed | Reg. No. | Title | |||||
| AMTK.P0002JP .D1 | Japan | 2012-241637 | 11/1/2012 | 6151006 | METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR | |||||
| AMTK.P0002JP.D2 | Japan | 2015-080729 | 4/10/2015 | METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR | ||||||
| AMTK.P0002JP.D3 | Japan | 2017-184649 | 9/26/2017 | 6676022 | METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR | |||||
| AMTK.P0002JP.D3D1 | Japan | 2020-000328 | 1/6/2020 | METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR | ||||||
| AMTK.P0002JP.D4 | Japan | 2017-184650 | 9/26/2017 | METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR | ||||||
| AMTK.P0002US.C1 | United States of America | 13/185472 | 7/18/2011 | 9138460 | METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR | |||||
| AMTK.P0002US.D1 | United States of America | 12/775720 | 5/7/2010 | 8728495 | METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO |
| -12- |
| Docket Number | Country | Appl. No. | Date Filed | Reg. No. | Title | |||||
| BIOREACTOR | ||||||||||
| AMTK.P0002US.D2 | United States of America | 12/775736 | 5/7/2010 | 9545432 | METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR | |||||
| AMTK.P0002US.D2C1 | United States of America | 15/371994 | 12/7/2016 | 10052410 | METHODSAND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR | |||||
| AMTK.P0002US.D2C2 | United States of America | 16/038915 | 7/18/2018 | 10806824 | METHODSAND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR | |||||
| AMTK.P0002US.D2C3 | United States of America | 16/865926 | 5/4/2020 | METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR | ||||||
| AMTK.P0002US.D3 | United States of America | 12/775753 | 5/7/2010 | 8298560 | METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR | |||||
| AMTK.P0002US.D4 | United States of America | 12/775765 | 5/7/2010 | 9320776 | METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR |
| -13- |
| Docket Number | Country | Appl. No. | Date Filed | Reg. No. | Title | |||||
| AMTK.P0002US.D5 | United States of America | 12/775771 | 5/7/2010 | 9533024 | METHODSAND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR | |||||
| AMTK.P0003CN | China | 201280063195.3 | 6/20/2014 | FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE | ||||||
| AMTK.P0003CN.D1 | China | 201711263200.6 | 12/5/2017 | FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE | ||||||
| AMTK.P0003ECH | Switzerland | 12846950.9 | 2776556 | FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE | ||||||
| AMTK.P0003ECH.D1 | Switzerland | 17192969.8 | 3290511 | FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE | ||||||
| AMTK.P0003EDE | Germany | 12846950.9 | 2776556 | FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE | ||||||
| AMTK.P0003EDE.D1 | Germany | 17192969.8 | 3290511 | FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE | ||||||
| AMTK.P0003EES | Spain | 12846950.9 | 2776556 | FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE | ||||||
| AMTK.P0003EES.DI | Spain | 17192969.8 | 3290511 | FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE |
| -14- |
| Docket Number | Country | Appl. No. | Date Filed | Reg. No. | Title | |||||
| AMTK.P0003EFR | France | 12846950.9 | 2776556 | FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE | ||||||
| AMTK.P0003EFR.D1 | France | 17192969.8 | 3290511 | FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE | ||||||
| AMTK.P0003EGB | United Kingdom | 12846950.9 | 2776556 | FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE | ||||||
| AMTK.P0003EGB.D1 | United Kingdom | 17192969.8 | 3290511 | FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE | ||||||
| AMTK.P0003EHK | Hong Kong | 14111200.7 | 11/4/2014 | HKl 197832 | FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE | |||||
| AMTK.P0003EHK.D1 | Hong Kong | 18111368.1 | 9/5/2018 | HK1252036 | FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE | |||||
| AMTK.P0003EIE.D1 | Ireland | 17192969.8 | 3290511 | FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE | ||||||
| AMTK.P0003 EIT | Italy | 12846950.9 | 2776556 | FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE | ||||||
| AMTK.P0003EIT.D1 | Italy | 17192969.8 | 3290511 | FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE | ||||||
| AMTK.P0003EP | European Patent | 12846950.9 | 5/21/2014 | 2776556 | FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC |
| -15- |
| Docket Number | Country | Appl. No. | Date Filed | Reg. No. | Title | |||||
| Office | DISEASE | |||||||||
| AMTK.P0003EP.Dl | European Patent Office | 17192969.8 | 9/25/2017 | 3290511 | FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE | |||||
| AMTK.P0003EP.D2 | European Patent Office | 20186304.0 | 7/16/2020 | FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE | ||||||
| AMTK.P0003IN | India | 391 l/DELNP/2014 | 5/15/2014 | FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE | ||||||
| AMTK.P0003US | United States of America | 14/357558 | 5/9/2014 | FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE | ||||||
| AMTK.P0003US.D 1 | United States of America | 15/957741 | 4/19/2018 | FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE | ||||||
| AMTK.P0003US.Pl | United States of America | 61/557479 | 11/9/2011 | FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE | ||||||
| AMTK.P0003US.P2 | United States of America | 61/691391 | 8/21/2012 | FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE | ||||||
| AMTK.P0003WO | Patent Cooperation Treaty | PCT/US2012/064101 | 11/8/2012 | FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE | ||||||
| AMTK.P0004AU | Australia | 2013299505 | 2/2/2015 | 2013299505 | GENERATION OF CARTILAGE EX VIVO FROM FIBROBLASTS |
| -16- |
| Docket Number | Country | Appl. No. | Date Filed | Reg. No. | Title | |||||
| AMTK.P0004AU.Dl | Australia | 2017201708 | 3/13/2017 | 2017201708 | GENERATION OF CARTILAGE EX VIVO FROM FIBROBLASTS | |||||
| AMTK.P0004CA | Canada | 2881126 | 2/4/2015 | GENERATION OF CARTILAGE EX VIVO FROM FIBROBLASTS | ||||||
| AMTK.P0004CHK.D1 | Hong Kong | 42020009561.0 | 6/18/2020 | GENERATION OF CARTILAGE EX VIVO FROM FIBROBLASTS | ||||||
| AMTK.P0004CN | China | 201380047210.X | 3/11/2015 | GENERATION OF CARTILAGE EX VIVO FROM FIBROBLASTS | ||||||
| AMTK.P0004CN.D1 | China | 201911186070.X | 11/28/2019 | GENERATION OF CARTILAGE EX VIVO FROM FIBROBLASTS | ||||||
| AMTK.P0004EHK | Hong Kong | 15110635.3 | 10/28/2015 | GENERATION OF CARTILAGE EX VIVO FROM FIBROBLASTS | ||||||
| AMTK.P0004EP | European Patent Office | 13827360.2 | 3/4/2015 | GENERATION OF CARTILAGE EX VIVO FROM FIBROBLASTS | ||||||
| AMTK.P0004IN | India | 1321/DELNP/2015 | 2/18/2015 | GENERATION OF CARTILAGE EX VIVO FROM FIBROBLASTS | ||||||
| AMTK.P0004JP | Japan | 2015-526709 | 2/9/2015 | 6456826 | GENERATION OF CARTILAGE EX VIVO FROM FIBROBLASTS | |||||
| AMTK.P0004JP .D1 | Japan | 2018-032337 | 2/26/2018 | 6574502 | GENERATION OF CARTILAGE EX VIVO FROM FIBROBLASTS | |||||
| AMTK.P0004JP .D2 | Japan | 2019-149332 | 8/16/2019 | GENERATION OF CARTILAGE EX VIVO FROM FIBROBLASTS | ||||||
| AMTK.P0004US | United States of America | 13/962241 | 8/8/2013 | GENERATION OF CARTILAGE EX VIVO FROM FIBROBLASTS |
| -17- |
| Docket Number | Country | Appl. No. | Date Filed | Reg. No. | Title | |||||
| AMTK.P0004US.P1 | United States of America | 61/681731 | 8/10/2012 | GENERATION OF CARTILAGE EX VIVO FROM FIBROBLASTS | ||||||
| AMTK.P0004 WO | Patent Cooperation Treaty | PCT/US2013/054158 | 8/8/2013 | GENERATION OF CARTILAGE EX VIVO FROM FIBROBLASTS | ||||||
| AMTK.P0005AU | Australia | 2014281818 | 12/7/2015 | 2014281818 | ADIPOSE CELLS FOR CHONDROCYTE APPLICATIONS | |||||
| AMTK.P0005AU.D1 | Australia | 2019253856 | 10/23/2019 | ADIPOSE CELLS FOR CHONDROCYTE APPLICATIONS | ||||||
| AMTK.P0005CA | Canada | 2915249 | 12/11/2015 | ADIPOSE CELLS FOR CHONDROCYTE APPLICATIONS | ||||||
| AMTK.P0005CN | China | 201480039060.2 | 1/8/2016 | ADIPOSE CELLS FOR CHONDROCYTE APPLICATIONS | ||||||
| AMTK.P0005ECH | Switzerland | 14813201.2 | 3011015 | ADIPOSE CELLS FOR CHONDROCYTE APPLICATIONS | ||||||
| AMTK.P0005EDE | Germany | 14813201.2 | 3011015 | ADIPOSE CELLS FOR CHONDROCYTE APPLICATIONS | ||||||
| AMTK.P0005EES | Spain | 14813201.2 | 3011015 | ADIPOSE CELLS FOR CHONDROCYTE APPLICATIONS | ||||||
| AMTK.P0005EFR | France | 14813201.2 | 301’1015 | ADIPOSE CELLS FOR CHONDROCYTE APPLICATIONS | ||||||
| AMTK.P0005EGB | United Kingdom | 14813201.2 | 3011015 | ADIPOSE CELLS FOR CHONDROCYTE APPLICATIONS | ||||||
| AMTK.P0005EHK | Hong Kong | 16110257.9 | 8/29/2016 | ADIPOSE CELLS FOR CHONDROCYTE APPLICATIONS |
| -18- |
| Docket Number | Country | Appl. No. | Date Filed | Reg. No. | Title | |||||
| AMTK.P0005EIE | Ireland | 14813201.2 | 3011015 | ADIPOSE CELLS FOR CHONDROCYTE APPLICATIONS | ||||||
| AMTK.P0005EIT | Italy | 14813201.2 | 3011015 | ADIPOSE CELLS FOR CHONDROCYTE APPLICATIONS | ||||||
| AMTK.P0005EP | European Patent Office | 14813201.2 | 1/6/2016 | 3011015 | ADIPOSE CELLS FOR CHONDROCYTE APPLICATIONS | |||||
| AMTK.P0005IN | India | 201617001725 | 1/18/2016 | ADIPOSE CELLS FOR CHONDROCYTE APPLICATIONS | ||||||
| AMTK.P0005JP | Japan | 2016-521475 | 12/18/2015 | ADIPOSE CELLS FOR CHONDROCYTE APPLICATIONS | ||||||
| AMTK.P0005JP.D1 | Japan | 2020-119475 | 7/10/2020 | ADIPOSE CELLS FOR CHONDROCYTE APPLICATIONS | ||||||
| AMTK.P0005US | United States of America | 14/304247 | 6/13/2014 | 10206954 | ADIPOSE CELLS FOR CHONDROCYTE APPLICATIONS | |||||
| AMTK.P0005US.Cl | United States of America | 16/244333 | 1/10/2019 | ADIPOSE CELLS FOR CHONDROCYTE APPLICATIONS | ||||||
| AMTK.P0005US.P1 | United States of America | 61/836975 | 6/19/2013 | ADIPOSE CELLS FOR CHONDROCYTE APPLICATIONS | ||||||
| AMTK.P0005WO | Patent Cooperation Treaty | PCT/US2014/042322 | 6/13/2014 | ADIPOSE CELLS FOR CHONDROCYTE APPLICATIONS | ||||||
| AMTK.P0006AU | Australia | 2014317861 | 3/8/2016 | 2014317861 | GENE THERAPY FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS |
| -19- |
| Docket Number | Country | Appl. No. | Date Filed | Reg. No. | Title | |||||
| AMTK.P0006AU.Dl | Australia | 2019268095 | 11/20/2019 | GENE THERAPY FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS | ||||||
| AMTK.P0006CA | Canada | 2923857 | 3/9/2016 | GENE THERAPY FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS | ||||||
| AMTK.P0006CN | China | 201480057130.7 | 4/18/2016 | GENE THERAPY FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS | ||||||
| AMTK.P0006EHK | Hong Kong | 16112454.6 | 10/28/2016 | GENE THERAPY FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS | ||||||
| AMTK.P0006EP | European Patent Office | 14841529.2 | 4/5/2016 | GENE THERAPY FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS | ||||||
| AMTK.P0006IN | India | 201617011955 | 4/5/2016 | GENE THERAPY FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS | ||||||
| AMTK.P0006JP | Japan | 2016-542044 | 3/9/2016 | GENE THERAPY FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS | ||||||
| AMTK.P0006JP .D1 | Japan | 2020-033592 | 2/28/2020 | GENE THERAPY FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS |
| -20- |
| Docket Number | Country | Appl. No. | Date Filed | Reg. No. | Title | |||||
| AMTK.P0006US | United States of America | 14/917560 | 3/8/2016 | GENE THERAPY FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS | ||||||
| AMTK.P0006US.Pl | United States of America | 61/875509 | 9/9/2013 | GENE THERAPY FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS | ||||||
| AMTK.P0006WO | Patent Cooperation Treaty | PCT/US2014/054804 | 9/9/2014 | GENE THERAPY FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS | ||||||
| AMTK.P0007 AU | Australia | 2017207445 | 7/3/2018 | CELLULAR BLEND FOR THE REGENERATION OF CHONDROCYTESOR CARTILAGE TYPE CELLS | ||||||
| AMTK.P0007CA | Canada | 3011306 | 7/11/2018 | CELLULAR BLEND FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS | ||||||
| AMTK.P0007CN | China | 201780011692.1 | 8/16/2018 | CELLULAR BLEND. FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS | ||||||
| AMTK.P0007EHK | Hong Kong | 18115243.3 | 11/28/2018 | CELLULAR BLEND FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS |
| -21- |
| Docket Number | Country | Appl. No. | Date Filed | Reg. No. | Title | |||||
| AMTK.P0007EP | European Patent Office | 17739050.7 | 7/12/2018 | CELLULAR BLEND FOR THE REGENERATION OF CHONDROCYTESOR CARTILAGE TYPE CELLS | ||||||
| AMTK.P0007IN | India | 201817025735 | 7/10/2018 | CELLULAR BLEND FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS | ||||||
| AMTK.P0007JP | Japan | 2018-536724 | 7/13/2018 | CELLULAR BLEND FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS | ||||||
| AMTK.P0007US | United States of America | 16/068096 | 7/3/2018 | CELLULAR BLEND FOR THE REGENERATION OF CHONDROCYTESOR CARTILAGE TYPE CELLS | ||||||
| AMTK.P0007US.Pl | United States of America | 62/278635 | 1/14/2016 | CELLULAR BLEND FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS | ||||||
| AMTK.P0007US.P2 | United States of America | 62/413587 | 10/27/2016 | CELLULAR BLEND FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS | ||||||
| AMTK.P0007WO | Patent Cooperation Treaty | PCT/US2017/013449 | 1/13/2017 | CELLULAR BLEND FOR THE REGENERATION OF CHONDROCYTESOR CARTILAGE TYPE |
| -22- |
| Docket Number | Country | Appl. No. | Date Filed | Reg. No. | Title | |||||
| CELLS | ||||||||||
| AMTK.P0008CA.D1 | Canada | 2925550 | 3/30/2016 | 2925550 | METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR | |||||
| AMTK.P0008CA.D2 | Canada | 3019254 | 10/1/2018 | 3019254 | USE OF CHONDROCYTE-LIKE CELLS TO TREAT A JOINT IN NEED OF REPAIR | |||||
| AMTK.P0008ECH | Switzerland | 07763383.2 | 1989289 | METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR | ||||||
| AMTK.P0008ECH.D 1 | Switzerland | 16195838.4 | 3146939 | METHODSAND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR | ||||||
| AMTK.P0008EDE | Germany | 07763383.2 | 1989289 | METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR | ||||||
| AMTK.P0008EDE.D1 | Germany | 16195838.4 | 3146939 | METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR |
| -23- |
| Docket Number | Country | Appl. No. | Date Filed | Reg. No. | Title | |||||
| AMTK.P0008EES | Spain | 07763383.2 | 1989289 | METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR | ||||||
| AMTK.P0008EES.D1 | Spain | 16195838.4 | 3146939 | METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR | ||||||
| AMTK.P0008EFR | France | 07763383.2 | 1989289 | METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR | ||||||
| AMTK.P0008EFR.D1 | France | 16195838.4 | 3146939 | METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR | ||||||
| AMTK.P0008EGB | United Kingdom | 07763383.2 | 1989289 | METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR | ||||||
| AMTK.P0008EGB.D1 | United Kingdom | 16195838.4 | 3146939 | METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR | ||||||
| AMTK.P0008EHK.D1 | Hong Kong | 17108880.7 | 9/4/2017 | HK1236375 | METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO |
| -24- |
| Docket Number | Country | Appl. No. | Date Filed | Reg. No. | Title | |||||
| BIOREACTOR | ||||||||||
| AMTK.P0008EIT | Italy | 07763383.2 | 1989289 | METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR | ||||||
| AMTK.P0008EIT.D1 | Italy | 16195838.4 | 3146939 | METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR | ||||||
| AMTK.P0008EP.Dl | European Patent Office | 16195838.4 | 10/26/2016 | 3146939 | METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR | |||||
| AMTK.P00 l 7EP | European Patent Office | 19795975.2 | 11/23/2020 | FIBROBLAST DELIVERY OF TUMOR INHIBITORY AGENTS | ||||||
| AMTK.P00 l 7US | United States of America | 17/052830 | 11/4/2020 | FIBROBLAST DELIVERY OF TUMOR INHIBITORY AGENTS | ||||||
| AMTK.P0017US.Pl | United States of America | 62/666786 | 5/4/2018 | FIBROBLAST DELIVERY OF TUMOR INHIBITORY AGENTS | ||||||
| AMTK.P00 l 7WO | Patent Cooperation Treaty | PCT/US2019/030585 | 5/3/2019 | FIBROBLAST DELIVERY OF TUMOR INHIBITORY AGENTS |
| -25- |
| Docket Number | Country | Appl. No. | Date Filed | Reg. No. | Title | |||||
| AMTK.P00 l 8EP | European Patent Office | 19795797.0 | 11/23/2020 | DE-DIFFERENTIATED FIBROBLAST- CONDITIONED MEDIA FOR STIMULATION OF DISC REGENERATION | ||||||
| AMTK.P00 l 8US | United States of America | 17/052841 | 11/4/2020 | DE-DIFFERENTIATED FIBROBLAST- CONDITIONED MEDIA FOR STIMULATION OF DISC REGENERATION | ||||||
| AMTK.P00 l 8US.Pl | United States of America | 62/666777 | 5/4/2018 | DE-DIFFERENTIATED FIBROBLAST- CONDITIONED MEDIA FOR STIMULATION OF DISC REGENERATION | ||||||
| AMTK.P00 l 8WO | Patent Cooperation Treaty | PCT/US2019/030570 | 5/3/2019 | DE-DIFFERENTIATED FIBROBLAST- CONDITIONED MEDIA FOR STIMULATION OF DISC REGENERATION | ||||||
| AMTK.P00 l 9EHK | Hong Kong | INTRADISCAL T- REGULATORY CELL ADMINISTRATION FOR TREATMENT OF DISC DEGENERATIVE DISEASE | ||||||||
| AMTK.P00 l 9EP | European Patent Office | 19796226.9 | 11/24/2020 | INTRADISCAL T- REGULATORY CELL ADMINISTRATION FOR TREATMENT OF DISC DEGENERATIVE DISEASE |
| -26- |
| Docket Number | Country | Appl. No. | Date Filed | Reg. No. | Title | |||||
| AMTK.P00 l 9US | United States of America | 17/052845 | 11/4/2020 | INTRADISCAL T- REGULATORY CELL ADMINISTRATION FOR TREATMENT OF DISC DEGENERATIVE DISEASE | ||||||
| AMTK.P00 l 9US.Pl | United States of America | 62/666807 | 5/4/2018 | INTRADISCAL T REGULATORY CELL ADMINISTRATION FOR TREATMENT OF DISC DEGENERATIVE DISEASE | ||||||
| AMTK.P0019WO | Patent Cooperation Treaty | PCT/US2019/030564 | 5/3/2019 | INTRADISCAL T- REGULATORY CELL ADMINISTRATION FOR TREATMENT OF DISC DEGENERATIVE DISEASE | ||||||
| AMTK.P0020EP | European Patent Office | 19796689.8 | 11/24/2020 | ENHANCEMENT OF FIBROBLAST PLASTICITY FOR TREATMENT OF DISC DEGENERATION | ||||||
| AMTK.P0020US | United States of America | 17/052854 | 11/4/2020 | ENHANCEMENT OF FIBROBLAST PLASTICITY FOR TREATMENT OF DISC DEGENERATION | ||||||
| AMTK.P0020US.P1 | United States of America | 62/666816 | 5/4/2018 | ENHANCEMENT OF FIBROBLAST PLASTICITY FOR TREATMENT OF DISC DEGENERATION | ||||||
| AMTK.P0020WO | Patent Cooperation Treaty | PCT/US2019/030577 | 5/3/2019 | ENHANCEMENT OF FIBROBLAST PLASTICITY FOR TREATMENT OF DISC DEGENERATION |
| -27- |
| Docket Number | Country | Appl. No. | Date Filed | Reg. No. | Title | |||||
| AMTK.P0025AU | Australia | 2019332928 | 3/11/2021 | CHIMERIC ANTIGEN RECEPTOR FIBROBLAST CELLS FOR TREATMENT OF CANCER | ||||||
| AMTK.P0025CA | Canada | 3111213 | 2/26/2021 | CHIMERIC ANTIGEN RECEPTOR FIBROBLAST CELLS FOR TREATMENT OF CANCER | ||||||
| AMTK.P0025EP | European Patent Office | 19853816.7 | 3/24/2021 | CHIMERIC ANTIGEN RECEPTOR FIBROBLAST CELLS FOR TREATMENT OF CANCER | ||||||
| AMTK.P0025US | United States of America | 17/271529 | 2/25/2021 | CHIMERIC ANTIGEN RECEPTOR FIBROBLAST CELLS FOR TREATMENT OF CANCER | ||||||
| AMTK.P0025US.Pl | United States of America | 62/723105 | 8/27/2018 | CHIMERIC ANTIGEN RECEPTOR FIBROBLAST CELLS FOR TREATMENT OF CANCER | ||||||
| AMTK.P0025US.P2 | United States of America | 62/820636 | 3/19/2019 | CHIMERIC ANTIGEN RECEPTOR FIBROBLAST CELLS FOR TREATMENT OF CANCER | ||||||
| AMTK.P0025WO | Patent Cooperation Treaty | PCT/US2019/0483l l | 8/27/2019 | CHIMERIC ANTIGEN RECEPTOR FIBROBLAST CELLS FOR TREATMENT OF CANCER |
| -28- |
| Docket Number | Country | Appl. No. | Date Filed | Reg. No. | Title | |||||
| AMTK.P0033US.Pl | United States of America | 62/793545 | 1/17/2019 | FIBROBLASTS AND MACROVESICLES THEREOF FOR REDUCTION OF TOXICITY ASSOCIATED WITH CANCER INNUMOTHERAPY | ||||||
| AMTK.P0033WO | Patent Cooperation Treaty | PCT/US2020/014018 | 1/17/2020 | FIBROBLASTS AND MICROVESICLES THEREOF FOR REDUCTION OF TOXICITY ASSOCIATED WITH CANCER INNUMOTHERAPY | ||||||
| AMTK.P0039US.Pl | United States of America | 62/839716 | 4/28/2019 | FIBROBLAST CELL THERAPY FOR TREATMENT OF OSTEOPOROSIS | ||||||
| AMTK.P0039WO | Patent Cooperation Treaty | PCT/US2020/030063 | 4/27/2020 | FIBROBLAST CELL THERAPY FOR TREATMENT OF OSTEOPOROSIS | ||||||
| AMTK.P004 l US.Pl | United States of America | 62/929828 | 11/2/2019 | FIBROBLAST- DERIVED UNIVERSAL IMMUNOLOGICAL COMPOSITION | ||||||
| AMTK.P004 l WO | Patent Cooperation Treaty | PCT/US2020/058492 | 11/2/2020 | FIBROBLAST- DERIVED UNIVERSAL IMMUNOLOGICAL COMPOSITION |
| -29- |
| Docket Number | Country | Appl. No. | Date Filed | Reg. No. | Title | |||||
| AMTK.P0042US | United States of America | 17/022897 | 9/16/2020 | TREATMENT OF DISC DEGENERATIVE DISEASE AND STIMULATION OF PROTEOGL YCAN SYNTHESIS BY FIBROBLAST CONDITIONED MEDIA AND FORMULATIONS THEREOF | ||||||
| AMTK.P0042US.Pl | United States of America | 62/901164 | 9/16/2019 | TREATMENT OF DISC DEGENERATIVE DISEASE AND STIMULATION OF PROTEOGLYCAN SYNTHESIS BY FIBROBLAST CONDITIONED MEDIA AND FORMULATIONS THEREOF | ||||||
| AMTK.P0042WO | Patent Cooperation Treaty | PCT/US2020/051036 | 9/16/2020 | TREATMENT OF DISC DEGENERATIVE DISEASE AND STIMULATION OF PROTEOGLYCAN SYNTHESIS BY FIBROBLAST CONDITIONED MEDIA AND FORMULATIONS THEREOF | ||||||
| AMTK.P0044US.Pl | United States of America | 62/929830 | 11/2/2019 | INTRATUMORAL ADMINISTRATION OF IMMUNE CELLULAR THERAPEUTICS | ||||||
| AMTK.P0044 WO | Patent Cooperation Treaty | PCT/US2020/058497 | 11/2/2020 | INTRATUMORAL ADMINISTRATION OF IMMUNE CELLULAR THERAPEUTICS |
| -30- |
| Docket Number | Country | Appl. No. | Date Filed | Reg. No. | Title | |||||
| AMTK.P0045US.Pl | United States of America | FIBROBLAST DELIVERY OF HYPERACUTE REJECTION INDUCING PAYLOAD TO CANCER CELLS | ||||||||
| AMTK.P0048US.P1 | United States of America | 62/953841 | 12/26/2019 | AUGMENTATION OF FIBROBLAST MEDIATED REGENERATION OF INTRAVERTEBRAL DISCS | ||||||
| AMTK.P0048WO | Patent Cooperation Treaty | PCT/US2020/067225 | 12/28/2020 | AUGMENTATION OF FIBROBLAST MEDIATED REGENERATION OF INTRAVERTEBRAL DISCS | ||||||
| AMTK.P0054US.Pl | United States of America | 62/914523 | 10/13/2019 | CANNABIDIOL ADJUVANT THERAPY FOR TREATMENT OF DISC DEGENERATIVE DISEASE | ||||||
| AMTK.P0054WO | Patent Cooperation Treaty | PCT/US2020/055313 | 10/13/2020 | CANNABIDIOL ADJUVANT THERAPY FOR TREATMENT OF DISC DEGENERATIVE DISEASE | ||||||
| AMTK.P0055US | United States of America | 16887720 | 5/29/2020 | CONCURRENT ACTIVATION OF REGENERATIVE AND TOLEROGENIC PROCESSES BY FIBROBLAST-BASED COMPOSITIONS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | ||||||
| AMTK.P0055US.Pl | United States of America | 62855010 | 5/31/2019 | CONCURRENT ACTIVATION OF REGENERATIVE AND TOLEROGENIC |
| -31- |
| Docket Number | Country | Appl. No. | Date Filed | Reg. No. | Title | |||||
| PROCESSES BY FIBROBLAST-BASED COMPOSITIONS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | ||||||||||
| AMTK.P0055WO | Patent Cooperation Treaty | PCT/US2020/035234 | 5/29/2020 | CONCURRENT ACTIVATION OF REGENERATIVE AND TOLEROGENIC PROCESSES BY FIBROBLAST-BASED COMPOSITIONS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | ||||||
| AMTK.P006 l US.Pl | United States of America | 62/977604 | 2/17/2020 | TELOMERE LENGTH MODULATION USING FIBROBLASTS AND DERIVITAVES THEREOF | ||||||
| AMTK.P0061 WO | Patent Cooperation Treaty | PCT/US2021/018160 | 2/16/2021 | TELOMERE LENGTH MODULATION USING FIBROBLASTS | ||||||
| AMTK.P0074US.Pl | United States of America | 63/017918 | 4/30/2020 | IMMUNOTHERAPEUTI C METHODS AND COMPOSITIONS FOR TARGETING CANCER FIBROBLASTS | ||||||
| AMTK.P0074WO | Patent Cooperation Treaty | PCT/US2021/070496 | 4/30/2021 | IMMUNOTHERAPEUTI C METHODS AND COMPOSITIONS FOR TARGETING CANCER FIBROBLASTS | ||||||
| AMTK.P0077US.Pl | United States of America | Closed duplicate case | CANCER FIBROBLAST SPECIFIC CANCER IMMUNOTHERAPY | |||||||
| P03351AU0 | Australia | 2007212085 | 7/29/2008 | 2007212085 | METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO |
| -32- |
| Docket Number | Country | Appl. No. | Date Filed | Reg. No. | Title | |||||
| BIOREACTOR | ||||||||||
| P03351CA0 | Canada | 2641170 | 7/25/2008 | 2641170 | METHODS AND COMPOSITJONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR | |||||
| P03351CN0 | China | 200780004506.8 | 7/31/2008 | ZL 200780004506.8 | METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR | |||||
| P03351EP0 | European Patent Office | 07763383.2 | 9/2/2008 | 1989289 | METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR | |||||
| P03351HK0 | Hong Kong | 09104307.l | 5/11/2009 | HKl 125406 | METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR | |||||
| P03351IN0 | India | 690 l/DELNP/2008 | 8/12/2008 | METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR | ||||||
| P03351JP0 | Japan | 2008-554464 | 8/6/2008 | 5269612 | METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR |
| -33- |
| Docket Number | Country | Appl. No. | Date Filed | Reg. No. | Title | |||||
| P03351US0 | United States of America | 60/771172 | 2/7/2006 | METHOD FOR REPAIRING AN INTERVERTEBRAL DISC | ||||||
| P0335 l US1 | United States of America | 11/671082 | 2/5/2007 | 7850983 | METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR | |||||
| P03351WO0 | Patent Cooperation Treaty | PCT/US2007/061590 | 2/5/2007 | METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR |
[End of Schedule 1.}
| -34- |
Schedule 2
SpinalCyte Licensed IP
| Docket Number | Country | Appl. No. | Date Filed | Patent No. | Title | |||||
| AMTK.P0009AU | Australia | 2018207541 | 7/16/2019 | METHODS OF ENHANCING FIBROBLAST THERAPEUTIC ACTIVITY | ||||||
| AMTK.P0009CA | Canada | 3049768 | 7/9/2019 | METHODS OF ENHANCING FIBROBLAST THERAPEUTIC ACTIVITY | ||||||
| AMTK.P0009CN | China | 201880013348.0 | 8/22/2019 | METHODS OF ENHANCING FIBROBLAST THERAPEUTIC ACTIVITY | ||||||
| AMTK.P0009EHK | Hong Kong | 62020004216.1 | 3/13/2020 | METHODS OF ENHANCING FIBROBLAST THERAPEUTIC ACTIVITY | ||||||
| AMTK.P0009EP | European Patent Office | 18738916.8 | 7/24/2019 | METHODS OF ENHANCING FIBROBLAST THERAPEUTIC ACTIVITY | ||||||
| AMTK.P0009IN | India | 201917032228 | 8/8/2019 | METHODS OF ENHANCING FIBROBLAST THERAPEUTIC ACTIVITY | ||||||
| AMTK.P0009JP | Japan | 2019-558339 | 7/10/2019 | METHODS OF ENHANCING FIBROBLAST THERAPEUTIC ACTIVITY | ||||||
| AMTK.P0009US | United States of America | 15/868420 | 1/11/2018 | METHODS OF ENHANCING FIBROBLAST THERAPEUTIC ACTIVITY | ||||||
| AMTK.P0009US.Cl | United States of America | METHODS OF ENHANCING FIBROBLAST THERAPEUTIC ACTIVITY |
| -35- |
| Docket Number | Country | Appl. No. | Date Filed | Patent No. | Title | |||||
| AMTK.P0009US.Pl | United States of America | 62/445133 | 1/11/2017 | METHODS OF ENHANCING FIBROBLAST THERAPEUTIC ACTIVITY | ||||||
| AMTK.P0009WO | Patent Cooperation Treaty | PCT/US2018/013357 | 1/11/2018 |
; | METHODS OF ENHANCING FIBROBLAST THERAPEUTIC ACTIVITY | |||||
| AMTK.P00l0AU | Australia | 2018254498 | 9/17/2019 | STIMULATION OF ANGIOGENESIS BY FIBROBLAST DERIVED EXOSOMES | ||||||
| AMTK.P00lOCA | Canada | 3058783 | 10/1/2019 | STIMULATION OF ANGIOGENESIS BY FIBROBLAST DERIVED EXOSOMES | ||||||
| AMTK.PO0lOCHK | Hong Kong | 62020007292.9 | 5/12/2020 | STIMULATION OF ANGIOGENESIS BY FIBROBLAST DERIVED EXOSOMES | ||||||
| AMTK.P00lOCN | China | 201880025815.1 | 10/18/2019 | STIMULATION OF ANGIOGENESIS BY FIBROBLAST DERIVED EXOSOMES | ||||||
| AMTK.P00lOEP | European Patent Office | 18787206.4 | 10/8/2019 | STIMULATION OF ANGIOGENESIS BY FIBROBLAST DERIVED EXOSOMES | ||||||
| AMTK.P00l0IN | India | 201917042021 | 10/17/2019 | STIMULATION OF ANGIOGENESIS BY FIBROBLAST DERIVED EXOSOMES | ||||||
| AMTK.P00lOJP | Japan | 2019-556899 | 10/18/2019 | STIMULATION OF ANGIOGENESIS BY FIBROBLAST DERIVED EXOSOMES | ||||||
| AMTK.P00lOUS | United States of America | 16/495371 | 9/18/2019 | STIMULATION OF ANGIOGENESIS BY FIBROBLAST DERIVED EXOSOMES |
| -36- |
| Docket Number | Country | Appl. No. | Date Filed | Patent No. | Title | |||||
| AMTK.P00l0US.Pl | United States of America | 62/487143 | 4/19/2017 | STIMULATION OF ANGIOGENESIS BY FIBROBLAST DERIVED EXOSOMES | ||||||
| AMTK.P00l0WO | Patent Cooperation Treaty | PCT/US2018/028358 | 4/19/2018 | STIMULATION OF ANGIOGENESIS BY FIBROBLAST DERIVED EXOSOMES | ||||||
| AMTK.P00llAU | Australia | 2018375151 | 5/20/2020 | INTERACTION OF FIBROBLASTS AND IMMUNE CELLS FOR ACTIVATION AND USES THEREOF | ||||||
| AMTK.P00llCA | Canada | 3083354 | 5/22/2020 | INTERACTION OF FIBROBLASTS AND IMMUNE CELLS FOR ACTIVATION AND USES THEREOF | ||||||
| AMTK.P00llCHK | Hong Kong | 62020021460.4 | 12/2/2020 | INTERACTION OF FIBROBLASTS AND IMMUNE CELLS FOR ACTIVATION AND USES THEREOF | ||||||
| AMTK.P00llCN | China | 201880086376.5 | 7/13/2020 | INTERACTION OF FIBROBLASTS AND IMMUNE CELLS FOR ACTIVATION AND USES THEREOF | ||||||
| AMTK.P00llEP | European Patent Office | 18884660.4 | 6/5/2020 | INTERACTION OF FIBROBLASTS AND IMMUNE CELLS FOR ACTIVATION AND USES THEREOF | ||||||
| AMTK.P00lllN | India | 202017027209 | 6/26/2020 | INTERACTION OF FIBROBLASTS AND IMMUNE CELLS FOR ACTIVATION AND USES THEREOF | ||||||
| AMTK.P00llJP | Japan | 2020-529293 | 5/28/2020 | INTERACTION OF FIBROBLASTS AND IMMUNE CELLS FOR ACTIVATION AND USES THEREOF | ||||||
| AMTK.P00llUS | United States of America | 16/765060 | 5/18/2020 | INTERACTION OF FIBROBLASTS AND IMMUNE CELLS FOR ACTIVATION AND USES THEREOF |
| -37- |
| Docket Number | Country | Appl. No. | Date Filed | Patent No. | Title | |||||
| AMTK.P00llUS.Pl | United States of America | 62/591858 | 11/29/2017 | INTERACTION OF FIBROBLASTS AND IMMUNE CELLS FOR ACTIVATION AND USES THEREOF | ||||||
| AMTK.P0011US.P2 | United States of America | INTERACTION OF FIBROBLASTS AND IMMUNE CELLS FOR ACTIVATION AND USES THEREOF | ||||||||
| AMTK.P00llWO | Patent Cooperation Treaty | PCT/US2018/063001 | 11/29/2018 | INTERACTION OF FIBROBLASTS AND IMMUNE CELLS FOR ACTIVATION AND USES THEREOF | ||||||
| AMTK.P0016AU | Australia | 2018388979 | 6/22/2020 | AUGMENTATION OF FIBROBLAST REGENERATIVE ACTIVITY | ||||||
| AMTK.P0016CA | Canada | 6/16/2020 | AUGMENTATION OF FIBROBLAST REGENERATIVE ACTIVITY | |||||||
| AMTK.P0016CHK | Hong Kong | AUGMENTATION OF FIBROBLAST REGENERATIVE ACTIVITY | ||||||||
| AMTK.P0016CN | China | 201880086500.8 | 7/14/2020 | AUGMENTATION OF FIBROBLAST REGENERATIVE ACTIVITY | ||||||
| AMTK.P0016EP | European Patent. Office | 18892707.3 | 6/11/2020 | AUGMENTATION OF FIBROBLAST REGENERATIVE ACTIVITY | ||||||
| AMTK.P0016IN | India | 202017026981 | 6/25/2020 | AUGMENTATION OF FIBROBLAST REGENERATIVE ACTIVITY | ||||||
| AMTK.P0016JP | Japan | 2020-534217 | 6/19/2020 | AUGMENTATION OF FIBROBLAST REGENERATIVE ACTIVITY | ||||||
| AMTK.P0016US | United States of America | 16/770495 | 6/5/2020 | AUGMENTATION OF FIBROBLAST REGENERATIVE ACTIVITY |
| -38- |
| Docket Number | Country | Appl. No. | Date Filed | Patent No. | Title | |||||
| AMTK.P0016US.Pl | United States of America | 62/608031 | 12/20/2017 | AUGMENTATION OF FIBROBLAST REGENERATIVE ACTIVITY | ||||||
| AMTK.P0016WO | Patent Cooperation Treaty | PCT/US2018/065931 | 12/17/2018 | AUGMENTATION OF FIBROBLAST REGENERATIVE ACTIVITY | ||||||
| AMTK.P0021CA | Canada | 3099387 | 11/4/2020 | PAIN REDUCING EFFECTS OF FIBROBLASTS AND THEREOF FOR TREATMENT OF PAIN | ||||||
| AMTK.P0021US | United States of America | 17/052859 | 11/4/2020 | PAIN REDUCING EFFECTS OF FIBROBLASTS AND TREATMENT OF PAIN | ||||||
| AMTK.P0021US.Pl | United States of America | 62/666828 | 5/4/2018 | PAIN REDUCING EFFECTS OF FIBROBLASTS AND THEREOF FOR TREATMENT OF PAIN | ||||||
| AMTK.P0021WO | Patent Cooperation Treaty | PCT/US2019/030596 | 5/3/2019 | PAIN REDUCING EFFECTS OF FIBROBLASTS AND THEREOF FOR TREATMENT OF PAIN | ||||||
| AMTK.P0022CA | Canada | 3103823 | 12/14/2020 | USE OF FIBROBLASTS AND/OR MODIFIED FIBROBLASTS FOR THREE DIMENSIONAL TISSUE PRINTING | ||||||
| AMTK.P0022EP | European Patent Office | USE OF FIBROBLASTS AND/OR MODIFIED FIBROBLASTS FOR THREE DIMENSIONAL TISSUE PRINTING | ||||||||
| AMTK.P0022US | United States of America | 17/251587 | 12/11/2020 | USE OF FIBROBLASTS AND/OR MODIFIED FIBROBLASTS FOR THREE DIMENSIONAL TISSUE PRINTING |
| -39- |
| Docket Number | Country | Appl. No. | Date Filed | Patent No. | Title | |||||
| AMTK.P0022US.Pl | United States of America | 62/684844 | 6/14/2018 | USE OF FIBROBLASTS AND/OR MODIFIED FIBROBLASTS FOR THREE DIMENSIONAL TISSUE PRINTING | ||||||
| AMTK.P0022WO | Patent Cooperation Treaty | PCT/US2019/037310 | 6/14/2019 | USE OF FIBROBLASTS AND/OR MODIFIED FIBROBLASTS FOR THREE DIMENSIONAL TISSUE PRINTING | ||||||
| AMTK.P0023AU | Australia | METHODS AND COMPOSITIONS FOR TREATMENT OF TYPE 1 DIABETES USING FIBROBLASTS AS FACILITATORS OF ISLET ENGRAFTMENT | ||||||||
| AMTK.P0023CA | Canada | METHODS AND COMPOSITIONS FOR TREATMENT OF TYPE 1 DIABETES USING FIBROBLASTS AS FACILITATORS OF ISLET ENGRAFTMENT | ||||||||
| AMTK.P0023EP | European Patent Office | METHODS AND COMPOSITIONS FOR TREATMENT OF TYPE 1 DIABETES USING FIBROBLASTS AS FACILITATORS OF ISLET ENGRAFTMENT | ||||||||
| AMTK.P0023JP | Japan | METHODS AND COMPOSITIONS FOR TREATMENT OF TYPE 1 DIABETES USING FIBROBLASTS AS FACILITATORS OF ISLET ENGRAFTMENT |
| -40- |
| Docket Number | Country | Appl. No. | Date Filed | Patent No. | Title | |||||
| AMTK.P0023US | United States of America | 17/309176 | 5/3/2021 | METHODS AND COMPOSITIONS FOR TREATMENT OF TYPE 1 DIABETES USING FIBROBLASTS AS FACILITATORS OF ISLET ENGRAFTMENT | ||||||
| AMTK.P0023US.Pl | United States of America | 62/755523 | 11/4/2018 | METHODS AND COMPOSITIONS FOR TREATMENT OF TYPE 1 DIABETES USING FIBROBLASTS AS FACILITATORS OF ISLET ENGRAFTMENT | ||||||
| AMTK.P0023WO | Patent Cooperation Treaty | PCT/US2019/059666 | 11/4/2019 | METHODS AND COMPOSITIONS FOR TREATMENT OF TYPE 1 DIABETES USING FIBROBLASTS AS FACILITATORS OF ISLET ENGRAFTMENT | ||||||
| AMTK.P0024AU | Australia | TREATMENT OF CACHEXIA USING FIBROBLAST CELLS AND PRODUCTS THEREOF | ||||||||
| AMTK.P0024CA | Canada | TREATMENT OF CACHEXIA USING FIBROBLAST CELLS AND PRODUCTS THEREOF | ||||||||
| AMTK.P0024EP | European Patent Office | TREATMENT OF CACHEXIA USING FIBROBLAST CELLS AND PRODUCTS THEREOF | ||||||||
| AMTK.P0024JP | Japan | TREATMENT OF CACHEXIA USING FIBROBLAST CELLS AND PRODUCTS THEREOF | ||||||||
| AMTK.P0024US | United States of America | 17/309177 | 5/3/2021 | TREATMENT OF CACHEXIA USING FIBROBLAST CELLS AND PRODUCTS THEREOF |
| -41- |
| Docket Number | Country | Appl. No. | Date Filed | Patent No. | Title | |||||
| AMTK.P0024US.Pl | United States of America | 62/755542 | 11/4/2018 | TREATMENT OF CACHEXIA USING FIBROBLAST CELLS AND PRODUCTS THEREOF | ||||||
| AMTK.P0024WO | Patent Cooperation Treaty | PCT/US2019/059678 | 11/4/2019 | TREATMENT OF CACHEXIA USING FIBROBLAST CELLS AND PRODUCTS THEREOF | ||||||
| AMTK.P0026AU | Australia | REGENERATIVE ABSCOPAL EFFECTS | ||||||||
| AMTK.P0026CA | Canada | REGENERATIVE ABSCOPAL EFFECTS | ||||||||
| AMTK.P0026EP | European Patent Office | 19881814.8 | REGENERATIVE ABSCOPAL EFFECTS | |||||||
| AMTK.P0026JP | Japan | REGENERATIVE ABSCOPAL EFFECTS | ||||||||
| AMTK.P0026US | United States of America | 17/309207 | 5/6/2021 | REGENERATIVE ABSCOPAL EFFECTS | ||||||
| AMTK.P0026US.Pl | United States of America | 62/757764 | 11/9/2018 | REGENERATIVE ABSCOPAL EFFECTS | ||||||
| AMTK.P0026WO | Patent Cooperation Treaty | PCT/US2019/060397 | 11/8/2019 | REGENERATIVE ABSCOPAL EFFECTS | ||||||
| AMTK.P0028AU | Australia | MEANS AND METHODS OF PREVENTING OR REVERSING AGING | ||||||||
| AMTK.P0028CA | Canada | MEANS AND METHODS OF PREVENTING OR REVERSING AGING | ||||||||
| AMTK.P0028EP | European Patent Office | 19882270.2 | MEANS AND METHODS OF PREVENTING OR REVERSING AGING | |||||||
| AMTK.P0028JP | Japan | MEANS AND METHODS OF PREVENTING OR REVERSING AGING | ||||||||
| AMTK.P0028US | United States of America | 17/309208 | 5/6/2021 | MEANS AND METHODS OF PREVENTING OR REVERSING AGING | ||||||
| AMTK.P0028US.Pl | United States of America | 62/758240 | 11/9/2018 | MEANS AND METHODS OF PREVENTING OR REVERSING AGING |
| -42- |
| Docket Number | Country | Appl. No. | Date Filed | Patent No. | Title | |||||
| AMTK.P0028WO | Patent Cooperation Treaty | PCT/US2019/060446 | 11/8/2019 | MEANS AND METHODS OF PREVENTING OR REVERSING AGING | ||||||
| AMTK.P0029US.Pl | United States of America | 62/791207 | 1/11/2019 | FIBROBLAST REGENERATIVE CELLS | ||||||
| AMTK.P0029WO | Patent Cooperation Treaty | PCT/US2020/013315 | 1/13/2020 | FIBROBLAST REGENERATIVE CELLS | ||||||
| AMTK.P0030US.Pl | United States of America | 62/839644 | 4/27/2019 | SELECTION OF FIBROBLAST DONORS FOR OPTIMIZATION OF ALLOGENEIC FIBROBLAST MEDIATED REGENERATION | ||||||
| AMTK.P0030WO | Patent Cooperation Treaty | PCT/US2020/030041 | 4/27/2020 | SELECTION OF FIBROBLAST DONORS FOR OPTIMIZATION OF ALLOGENEIC FIBROBLAST MEDIATED REGENERATION | ||||||
| AMTK.P0031US.Pl | United States of America | 62/780289 | 12/16/2018 | THERAPEUTIC USES OF GENE EDITED FIBROBLASTS | ||||||
| AMTK.P0031WO | Patent Cooperation Treaty | PCT/US2019/066575 | 12/16/2019 | THERAPEUTIC USES OF GENE EDITED FIBROBLASTS | ||||||
| AMTK.P0032AU | Australia | TREATMENT OF CEREBRAL HYPOXIA INCLUDING STROKE, CHRONIC TRAUMATIC ENCEPHALOPATHY, AND TRAUMATIC BRAIN INJURY | ||||||||
| AMTK.P0032CA | Canada | TREATMENT OF CEREBRAL HYPOXIA INCLUDING STROKE, CHRONIC TRAUMATIC ENCEPHALOPATHY, AND TRAUMATIC BRAIN INJURY |
| -43- |
| Docket Number | Country | Appl. No. | Date Filed | Patent No. | Title | |||||
| AMTK.P0032EP | European Patent Office | TREATMENT OF CEREBRAL HYPOXIA INCLUDING STROKE, CHRONIC TRAUMATIC ENCEPHALOPATHY, AND TRAUMATIC BRAIN INJURY | ||||||||
| AMTK.P0032JP | Japan | TREATMENT OF CEREBRAL HYPOXIA INCLUDING STROKE, CHRONIC TRAUMATIC ENCEPHALOPATHY, AND TRAUMATIC BRAIN INJURY | ||||||||
| AMTK.P0032US | United States of America | 17/309178 | 5/3/2021 | TREATMENT OF CEREBRAL HYPOXIA INCLUDING STROKE, CHRONIC TRAUMATIC ENCEPHALOPATHY, AND TRAUMATIC BRAIN INJURY | ||||||
| AMTK.P0032US.Pl | United States of America | 62/755553 | 11/4/2018 | TREATMENT OF CEREBRAL HYPOXIA INCLUDING STROKE, CHRONIC TRAUMATIC ENCEPHALOPATHY, AND TRAUMATIC BRAIN INJURY | ||||||
| AMTK.P0032WO | Patent Cooperation Treaty | PCT/US2019/059683 | 11/4/2019 | TREATMENT OF CEREBRAL HYPOXIA INCLUDING STROKE, CHRONIC TRAUMATIC ENCEPHALOPATHY, AND TRAUMATIC BRAIN INJURY | ||||||
| AMTK.P0034US | United States of America | 16/822746 | 3/18/2020 | TREATMENT OF OPIOID ADDICTION USING FIBROBLASTS AND PRODUCTS THEREOF | ||||||
| AMTK.P0034US.Pl | United States of America | 62/820721 | 3/19/2019 | TREATMENT OF OPIOID ADDICTION USING FIBROBLASTS AND PRODUCTS THEREOF |
| -44- |
| Docket Number | Country | Appl. No. | Date Filed | Patent No. | Title | |||||
| AMTK.P0034WO | Patent Cooperation Treaty | PCT/US2020/023332 | 3/18/2020 | TREATMENT OF OPIOID ADDICTION USING FIBROBLASTS AND PRODUCTS THEREOF | ||||||
| AMTK.P0035US | United | 16/913860 | 6/26/2020 | ADMINISTRATION OF | ||||||
| States of | FIBROBLASTS AND | |||||||||
| America | DERIVATIVES THEREOF | |||||||||
| FOR TREATMENT OF | ||||||||||
| TYPE 2 DIABETES | ||||||||||
| AMTK.P0035US.Pl | United | 62/867976 | 6/28/2019 | ADMINISTRATION OF | ||||||
| States of | FIBROBLASTS AND | |||||||||
| America | DERIVATIVES THEREOF | |||||||||
| FOR TREATMENT OF | ||||||||||
| TYPE 2 DIABETES | ||||||||||
| AMTK.P0035WO | Patent | PCT/US2020/039904 | 6/26/2020 | ADMINISTRATION OF | ||||||
| Cooperation | FIBROBLASTS AND | |||||||||
| Treaty | DERIVATIVES THEREOF | |||||||||
| FOR TREATMENT OF | ||||||||||
| TYPE 2 DIABETES | ||||||||||
| AMTK.P0036US | United States of America | 16/822811 | 3/18/2020 | TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND LUNG | ||||||
DEGENERATION USING ACTIVATED | ||||||||||
FIBROBLASTS AND EXOSOME DERIVATIVES THEREOF | ||||||||||
| AMTK.P0036US.Pl | United | 62/820763 | 3/19/2019 | TREATMENT OF | ||||||
| States of | CHRONIC | |||||||||
| America | OBSTRUCTIVE | |||||||||
| PULMONARY DISEASE | ||||||||||
| AND LUNG | ||||||||||
| DEGENERATION USING | ||||||||||
| ACTIVATED | ||||||||||
| FIBROBLASTS AND | ||||||||||
| EXOSOME DERIVATIVES | ||||||||||
| THEREOF |
| -45- |
| Docket Number | Country | Appl. No. | Date Filed | Patent No. | Title | |||||
| AMTK.P0036WO | Patent Cooperation Treaty | PCT/US2020/023339 | 3/18/2020 | TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND LUNG DEGENERATION USING | ||||||
ACTIVATED FIBROBLASTS AND EXOSOME DERIVATIVES THEREOF | ||||||||||
| AMTK.P0037US.Pl | United States of America | 62/845403 | 5/9/2019 | FIBROBLAST GENERATED PATIENT SPECIFIC VACCINES | ||||||
| AMTK.P0037WO | Patent Cooperation Treaty | PCT/US2020/032207 | 5/8/2020 | FIBROBLAST GENERATED PATIENT- SPECIFIC VACCINES | ||||||
| AMTK.P0038US.Pl | United States of | 62/839652 | 4/27/2019 | ENHANCEMENT OF FIBROBLAST | ||||||
| America | THERAPEUTIC ACTIVITY BY T CELL MODULATION | |||||||||
| AMTK.P0038WO | Patent | PCT/US2020/030045 | 4/27/2020 | ENHANCEMENT OF | ||||||
| Cooperation | FIBROBLAST | |||||||||
| Treaty | THERAPEUTIC ACTIVITY | |||||||||
| BY T CELL | ||||||||||
| MODULATION | ||||||||||
| AMTK.P0040US.Pl | United | 62/860252 | 6/12/2019 | ENHANCEMENT OF | ||||||
| States of | FIBROBLAST | |||||||||
| America | THERAPEUTIC ACTIVITY | |||||||||
| BY | ||||||||||
| RNA | ||||||||||
| AMTK.P0040WO | Patent | PCT/US2020/037467 | 6/12/2020 | ENHANCEMENT OF | ||||||
| Cooperation | FIBROBLAST | |||||||||
| Treaty | THERAPEUTIC ACTIVITY | |||||||||
| BY | ||||||||||
| RNA | ||||||||||
| AMTK.P0043US.Pl | United | 62/915292 | 10/15/2019 | PREVENTION OF | ||||||
| States of | RECURRENT | |||||||||
| America | MISCARRIAGES | |||||||||
| THROUGH | ||||||||||
| ADMINISTRATION OF | ||||||||||
| FIBROBLAST AND | ||||||||||
| FIBROBLAST EDUCATED | ||||||||||
| PATERNAL CELLS |
| -46- |
| Docket Number | Country | Appl. No. | Date Filed | Patent No. | Title | |||||
| AMTK.P0043WO | Patent Cooperation Treaty | PCT/US2020/055642 | 10/14/2020 | PREVENTION OF RECURRENT MISCARRIAGES THROUGH ADMINISTRATION OF FIBROBLAST AND | ||||||
| FIBROBLAST EDUCATED PATERNAL CELLS | ||||||||||
| AMTK.P0046US.Pl | United | 62/953836 | 12/26/2019 | PREVENTION AND | ||||||
| States of | TREATMENT OF KIDNEY | |||||||||
| America | FAILURE BY | |||||||||
| ADMINISTRATION OF | ||||||||||
| FIBROBLASTS AND | ||||||||||
| PRODUCTS THEREOF | ||||||||||
| AMTK.P0046WO | Patent | PCT/US2020/066585 | 12/22/2020 | PREVENTION AND | ||||||
| Cooperation | TREATMENT OF KIDNEY | |||||||||
| Treaty | FAILURE BY | |||||||||
| ADMINISTRATION OF | ||||||||||
| FIBROBLASTS AND | ||||||||||
| PRODUCTS THEREOF | ||||||||||
| AMTK.P0047US | United States of America | 16/887971 | 5/29/2020 | FIBROBLAST THERAPY FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | ||||||
| AMTK.P0047US.Pl | United States of America | 62/855014 | 5/31/2019 | FIBROBLAST THERAPY FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | ||||||
| AMTK.P0047WO | Patent Cooperation Treaty | PCT/US2020/035283 | 5/29/2020 | FIBROBLAST THERAPY FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | ||||||
| AMTK.P0049US.Pl | United | 62/864503 | 6/21/2019 | TREATMENT OF | ||||||
| States of | AUTISM SPECTRUM | |||||||||
| America | DISORDER AND | |||||||||
| ASSOCIATED | ||||||||||
| NEUROINFLAMMATION | ||||||||||
| USING FIBROBLASTS | ||||||||||
| AND DERIVATIVES | ||||||||||
| THEREOF |
| -47- |
| Docket Number | Country | Appl. No. | Date Filed | Patent No. | Title | |||||
| AMTK.P0049WO | Patent Cooperation Treaty | PCT/US2020/038967 | 6/22/2020 | TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED NEUROINFLAMMATION USING FIBROBLASTS AND DERIVATIVES THEREOF | ||||||
| AMTK.P0050US.Pl | United States of America | 62/953843 | 12/26/2019 | SUPRESSION OF INTERLEUKIN-17 PRODUCTION AND INHIBITION OF Th17 CELL GENERATION BY FIBROBLASTS AND PRODUCTS THEREOF | ||||||
| AMTK.P0050WO | Patent Cooperation Treaty | PCT/US2020/066591 | 12/22/2020 | SUPRESSION OF INTERLEUKIN-17 PRODUCTION AND INHIBITION OF Th17 CELL GENERATION BY FIBROBLASTS AND PRODUCTS THEREOF | ||||||
| AMTK.P0051US.Pl | United States of America | 62/953847 | 12/26/2019 | INHIBITION OF TNF- ALPHA BY FIBROBLASTS AND FIBROBLAST EXOSOMES | ||||||
| AMTK.P0051WO | Patent Cooperation Treaty | PCT/US2020/066602 | 12/22/2020 | INHIBITION OF TNF- ALPHA BY FIBROBLASTS AND FIBROBLAST EXOSOMES | ||||||
| AMTK.P0052US.Pl | United States of America | 62/915152 | 10/15/2019 | FIBROBLAST- BASED IMMUNOTHERAPY OF GRAVES DISEASE | ||||||
| AMTK.P0052WO | Patent Cooperation Treaty | PCT/US2020/055641 | 10/14/2020 | FIBROBLAST - BASED IMMUNOTHERAPY OF GRAVES DISEASE | ||||||
| AMTK.P0053US.Pl | United States of America | 62/935678 | 11/15/2019 | FIBROBLAST THERAPY FOR INFLAMMATORY BOWEL DISEASE | ||||||
| AMTK.P0053WO | Patent Cooperation Treaty | PCT/US2020/060748 | 11/16/2020 | FIBROBLAST THERAPY FOR INFLAMMATORY BOWEL DISEASE |
| -48- |
| Docket Number | Country | Appl. No. | Date Filed | Patent No. | Title | |||||
| AMTK.P0057US.Pl | United States of America | 62/914747 | 10/14/2019 | TREATMENT OF AUTOIMMUNITY AND TRANSPLANT REJECTION THROUGH ESTABLISHMENT AND/OR PROMOTION OF TOLEROGENIC PROCESSES BY FlBROBLAST-M EDIATED REPROGRAMMING OF ANTIGEN PRESENTING CELLS | ||||||
| AMTK.P0057WO | Patent Cooperation Treaty | PCT/US2020/055427 | 10/13/2020 | TREATMENT OF AUTOIMMUNITY AND TRANSPLANT REJECTION THROUGH ESTABLISHMENT AND/OR PROMOTION OF TOLEROGENIC PROCESSES BY FIBROBLAST-MEDIATED REPROGRAMMING OF ANTIGEN PRESENTING CELLS | ||||||
| AMTK.P0058US.P1 | United States of America | 62/936548 | 11/17/2019 | FIBROBLAST-BASED THERAPY AND TREATMENT AND PREVENTION OF STROKE | ||||||
| AMTK.P0058US.P2 | United States of America | 63/047813 | 7/2/2020 | FIBROBLAST-BASED THERAPY AND TREATMENT AND PREVENTION OF STROKE | ||||||
| AMTK.P0058WO | Patent Cooperation Treaty | PCT/US2020/060724 | 11/16/2020 | FIBROBLAST-BASED THERAPY AND TREATMENT AND PREVENTION OF STROKE | ||||||
| AMTK.P0059US.Pl | United States of America | 62/976048 | 2/13/2020 | TREATMENT AND PREVENTION OF CEREBRAL PALSY USING FIBROBLASTS |
| -49- |
| Docket Number | Country | Appl. No. | Date Filed | Patent No. | Title | |||||
| AMTK.P0059WO | Patent Cooperation Treaty | PCT/US2021/017998 | 2/12/2021 | TREATMENT OF CEREBRAL PALSY USING FIBROBLASTS | ||||||
| AMTK.P0060US.P1 | United States of America | 62/929250 | 11/1/2019 | FlBROBLAST-BASED THERAPY FOR TREATMENT OF SCLEROSING CHOLANGITIS | ||||||
| AMTK.P0060WO | Patent Cooperation Treaty | PCT/US2020/058500 | 11/2/2020 | FIBROBLAST-BASED THERAPY FOR TREATMENT OF SCLEROSING CHOLANGITIS | ||||||
| AMTK.P0062US.Pl | United States of America | 63/024440 | 5/13/2020 | FIBROBLAST BASED CELL THERAPY FOR TREATMENT OF PARKINSON’S DISEASE | ||||||
| AMTK.P0062WO | Patent Cooperation Treaty | PCT/US2021/070551 | 5/13/2021 | FIBROBLAST BASED CELL THERAPY FOR TREATMENT OF PARKINSON’S DISEASE | ||||||
| AMTK.P0063US.P1 | United States of America | 63/008970 | 4/13/2020 | TREATMENT OF ERECTILE DYSFUNCTION BY FIBROBLAST ADMINISTRATION | ||||||
| AMTK.P0063WO | Patent Cooperation Treaty | PCT/US2021/026752 | 4/10/2021 | TREATMENT OF ERECTILE DYSFUNCTION BY FIBROBLAST ADMINISTRATION | ||||||
| AMTK.P0064US.Pl | United States of America | 63/006957 | 4/8/2020 | METHODS AND COMPOSITIONS FOR ALLERGY AND ASTHMA TREATMENT USING FIBROBLASTS | ||||||
| AMTK.P0064WO | Patent Cooperation Treaty | PCT/US2021/025959 | 4/6/2021 | METHODS AND COMPOSITIONS FOR ALLERGY AND ASTHMA TREATMENT USING FIBROBLASTS |
| -50- |
| Docket Number | Country | Appl. No. | Date Filed | Patent No. | Title | |||||
| AMTK.P0065US.P1 | United States of America | 62/897428 | 9/9/2019 | FIBROBLAST AND FIBROBLAST- IMMUNOCYTE COMBINATIONS FOR TREATMENT OF SUBCONCUSSIVE- AND | ||||||
CONCUSSIVE ASSOCIATED NEUROLOGICAL | ||||||||||
| DAMAGE | ||||||||||
| AMTK.P0065WO | Patent | PCT/US2020/049949 | 9/9/2020 | FIBROBLAST AND | ||||||
| Cooperation | FIBROBLAST- | |||||||||
| Treaty | IMMUNOCYTE | |||||||||
| COMBINATIONS FOR | ||||||||||
| TREATMENT OF | ||||||||||
| SUBCONCUSSIVE- AND | ||||||||||
| CONCUSSIVE | ||||||||||
| ASSOCIATED | ||||||||||
| NEUROLOGICAL | ||||||||||
| DAMAGE | ||||||||||
| AMTK.P0066US.Pl | United | 62/897429 | 9/9/2019 | TREATMENT OF | ||||||
| States of | TRAUMATIC | |||||||||
| America | ENCEPHALOPATHY BY | |||||||||
| FIBROBLASTS AND | ||||||||||
| THERAPEUTIC | ||||||||||
| ADJUVANTS | ||||||||||
| AMTK.P0066WO | Patent | PCT/US2020/049990 | 9/9/2020 | TREATMENT OF | ||||||
| Cooperation | TRAUMATIC | |||||||||
| Treaty | ENCEPHALOPATHY BY | |||||||||
| FIBROBLASTS AND | ||||||||||
| THERAPEUTIC | ||||||||||
| ADJUVANTS | ||||||||||
| AMTK.POOG7 US.P1 | United | 63/033092 | 6/1/2020 | FIBROBLASTS AS A | ||||||
| States of | REGENERATIVE | |||||||||
| America | CELLULAR SOURCE FOR | |||||||||
| TREATMENT OF | ||||||||||
| BLINDNESS | ||||||||||
| AMTK.P0067WO | Patent | FIBROBLASTS AS A | ||||||||
| Cooperation | REGENERATIVE | |||||||||
| Treaty | CELLULAR SOURCE FOR | |||||||||
| TREATMENT OF | ||||||||||
| BLINDNESS | ||||||||||
| AMTK.P0068US.P1 | United | 63/015150 | 4/24/2020 | TREATMENT OF | ||||||
| States of | FRONTOTEMPORAL | |||||||||
| America | DEMENTIA USING | |||||||||
| FIBROBLASTS AND | ||||||||||
| PRODUCTS THEREOF |
| -51- |
| Docket Number | Country | Appl. No. | Date Filed | Patent No. | Title | |||||
| AMTK.P0068WO | Patent Cooperation Treaty | PCT/US2021/027980 | 4/19/2021 | TREATMENT OF FRONTOTEMPORAL DEMENTIA USING FIBROBLASTS AND PRODUCTS THEREOF | ||||||
| AMTK.P0069US.Pl | United States of America | 63/012200 | 4/19/2020 | MEANS AND METHODS OF AUGMENTATION OF FIBROBLAST THERAPEUTIC PROPERTIES USING EXTRACORPOREAL SHOCK WAVE THERAPY AND/OR TRANSFECTION OF BIOLOGICALLY RELEVANT MOLECULES | ||||||
| AMTK.P0069WO | Patent Cooperation Treaty | PCT/US2021/027654 | 4/16/2021 | MEANS AND METHODS OF AUGMENTATION OF FIBROBLAST THERAPEUTIC PROPERTIES USING EXTRACORPOREAL SHOCK WAVE THERAPY AND/OR TRANSFECTION OF BIOLOGICALLY RELEVANT MOLECULES | ||||||
| AMTK.P0070US.P1 | United States of America | 63/031782 | 5/29/2020 | FIBROBLAST THERAPY FOR PREVENTION AND REVERSION OF ANEURYSMS | ||||||
| AMTK.P0070WO | Patent Cooperation Treaty | FIBROBLAST THERAPY FOR PREVENTION AND REVERSION OF ANEURYSMS | ||||||||
| AMTK.P0071US.P1 | United States of America | 63/025092 | 5/14/2020 | TREATMENT OF OVARIAN FAILURE USING REGENERATIVE CELLS | ||||||
| AMTK.P0071WO | Patent Cooperation Treaty | PCT/US2021/070555 | 5/14/2021 | TREATMENT OF OVARIAN FAILURE USING REGENERATIVE CELLS |
| -52- |
| Docket Number | Country | Appl. No. | Date Filed | Patent No. | Title | |||||
| AMTK.P0072US.Pl | United States of America | 63/031810 | 5/29/2020 | AUGMENTATION OF FIBROBLAST CELL THERAPY EFFICACY BY MICROBIOME MANIPULATION | ||||||
| AMTK.P0072WO | Patent Cooperation Treaty | AUGMENTATION OF FIBROBLAST CELL THERAPY EFFICACY BY MICROBIOME MANIPULATION | ||||||||
| AMTK.P0073US.Pl | United States of America | TREATMENT OF CEREBRAL HEMORRHAGE USING FIBROBLASTS, MODIFIED FIBROBLASTS AND DERIVATIVES THEREOF | ||||||||
| AMTK.P0075 US.Pl | United States of America | 63/012202 | 4/19/2020 | GENE MODIFIED FIBROBLASTS FOR THERAPEUTIC APPLICATIONS | ||||||
| AMTK.P0075WO | Patent Cooperation Treaty | PCT/US2021/027990 | 4/19/2021 | GENE MODIFIED FIBROBLASTS FOR THERAPEUTIC APPLICATIONS | ||||||
| AMTK.P0076US.Pl | United States of America | 62/986339 | 3/6/2020 | FIBROBLAST AND TLR ACTIVATED FIBROBLAST TREATMENT OF VIRAL INDUCED ACUTE RESPIRATORY DISTRESS SYNDROME | ||||||
| AMTK.P0076WO | Patent Cooperation Treaty | PCT/US2021/020449 | 3/2/2021 | FIBROBLAST AND TLR ACTIVATED FIBROBLAST TREATMENT OF VIRAL INDUCED ACUTE RESPIRATORY DISTRESS SYNDROME | ||||||
| AMTK.P0078US.Pl | United States of America | 62/989118 | 3/13/2020 | GENERATION OF AUTOIMMUNE INHIBITORY T CELLS BY FIBROBLAST MEDIATED EDUCATION |
| -53- |
| Docket Number | Country | Appl. No. | Date Filed | Patent No. | Title | |||||
| AMTK.P0078WO | Patent Cooperation Treaty | PCT/US2021/022145 | 3/12/2021 | GENERATION OF AUTOIMMUNE INHIBITORY T CELLS BY FIBROBLAST MEDIATED EDUCATION | ||||||
| AMTK.P0079US.Pl | United States of America | 63/002134 | 3/30/2020 | PEPTIDES AND ADJUVANTS FOR AUGMENTATION OF FIBROBLAST THERAPY FOR CORONAVIRUS | ||||||
| AMTK.P0079US.P2 | United States of America | 63/003742 | 4/1/2020 | PEPTIDES AND ADJUVANTS FOR AUGMENTATION OF FIBROBLAST THERAPY FOR CORONAVIRUS | ||||||
| AMTK.P0079WO | Patent Cooperation Treaty | PCT/US2021/020457 | 3/2/2021 | PEPTIDES AND ADJUVANTS FOR AUGMENTATION OF FIBROBLAST THERAPY FOR CORONAVIRUS | ||||||
| AMTK.P0080US.Pl | United States of America | 63/003731 | 4/1/2020 | FIBROBLAST MEDIATED EXPANSION AND AUGMENTATION OF IMMUNE REGULATORY CELLS FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) | ||||||
| AMTK.P0080US.P2 | United States of America | 63/017068 | 4/29/2020 | FIBROBLAST MEDIATED EXPANSION AND AUGMENTATION OF IMMUNE REGULATORY CELLS FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) |
| -54- |
| Docket Number | Country | Appl. No. | Date Filed | Patent No. | Title | |||||
| AMTK.P0080WO | Patent Cooperation Treaty | PCT/US2021/020459 | 3/2/2021 | FIBROBLAST MEDIATED EXPANSION AND AUGMENTATION OF IMMUNE REGULATORY CELLS FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) | ||||||
| AMTK.P0081US.Pl | United States of America | TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME BY FIBROBLASTS AND ANTI-INFLAMMATORY ANTIGEN | ||||||||
| AMTK.P0082US.Pl | United States of America | 63/020198 | 5/5/2020 | REDUCTION OF CYTOKINE STORM AND PATHOLOGICAL INFLAMMATION INCLUDING CAUSED BY CORONAVIRUS USING SPHAGNUM AND EXTRACTS THEREOF | ||||||
| AMTK.P0082WO | Patent Cooperation Treaty | PCT/US2021/070504 | 5/4/2021 | REDUCTION OF CYTOKINE STORM AND PATHOLOGICAL INFLAMMATION INCLUDING CAUSED BY CORONAVIRUS USING SPHAGNUM AND EXTRACTS THEREOF | ||||||
| AMTK.P0083US.Pl | United States of America | 63/051845 | 7/14/2020 | AUGMENTATION OF FIBROBLAST THERAPEUTIC ACTIVITY BY COMPLEMENT BLOCKADE AND/OR INHIBITION | ||||||
| AMTK.P0084US.Pl | United States of America | 63/071333 | 8/27/2020 | DENTAL AND PERIODONTAL APPLICATION OF FIBROBLASTS |
| -55- |
| Docket Number | Country | Appl. No. | Date Filed | Patent No. | Title | |||||
| AMTK.P0085US.Pl | United States of America | 63/064538 | 8/12/2020 | Reduction of COVID-19 Coagulopathy and Other Inflammation Associated Coagulopathies by Administration of Fibroblasts | ||||||
| AMTK.P0086US.Pl | United | TREATMENT OF | ||||||||
| States of | ALOPECIA AND/OR | |||||||||
| America | STIMULATION OF HAIR | |||||||||
| FOLLICLE | ||||||||||
| REGENERATION BY | ||||||||||
| ADMINISTRATION OF | ||||||||||
| FIBROBLASTS AND/OR | ||||||||||
| PRODUCTS THEREOF |
[End of Schedule 2.]
| 56 |